Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel technology, designed to promote the regeneration of durable, natural-like cartilage in patients with painful knee cartilage injuries. The cell-free, off-the-shelf implant temporarily fills cartilage defects before gradually resorbing as surrounding tissue regenerates. Long-term MRI findings and peer-reviewed Phase II clinical data have provided evidence of cartilage maturation and durable structural repair, while the company has reported greater pain improvement than traditional microfracture. Regentis has treated 43 of 80 planned patients in its U.S. pivotal Phase III trial, with enrollment expected to conclude around the end of 2026, and is preparing for potential European commercialization under its existing CE Mark approval. The company is also scaling manufacturing following European regulatory approval of a new solvent-free process that it says increases production yield by 400%.
To view the full article, visit https://nnw.fm/JiVLN
About Regentis Biomaterials Ltd.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R) is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://nnw.fm/RGNT
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWireAustin, Texaswww.NetworkNewsWire.com512.354.7000 OfficeEditor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
